Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine

The changes in the severe acute respiratory syndrome coronavirus 2 and the tapering of immunity after vaccination have propelled the need for a booster dose vaccine. We aim to evaluate B and T cell immunogenicity and reactogenicity of mRNA-1273 COVID-19 vaccine (100 µg) as a third booster dose after...

Descripción completa

Detalles Bibliográficos
Autores principales: Tangsathapornpong, Auchara, Nanthapisal, Sira, Pontan, Kanassanan, Bunjoungmanee, Pornumpa, Neamkul, Yamonbhorn, Boonyarangkul, Arthit, Wanpen, Supattra, Fukpho, Waraphon, Jitpokasem, Sumana, Tharabenjasin, Phuntila, Jaru-Ampornpan, Peera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053262/
https://www.ncbi.nlm.nih.gov/pubmed/36992137
http://dx.doi.org/10.3390/vaccines11030553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053262/
https://www.ncbi.nlm.nih.gov/pubmed/36992137
http://dx.doi.org/10.3390/vaccines11030553

Ejemplares similares